vs
ANI PHARMACEUTICALS INC（ANIP）とShoals Technologies Group, Inc.（SHLS）の財務データ比較。上の社名をクリックして会社を切り替えられます
ANI PHARMACEUTICALS INCの直近四半期売上が大きい（$247.1M vs $148.3M、Shoals Technologies Group, Inc.の約1.7倍）。ANI PHARMACEUTICALS INCの純利益率が高く（11.1% vs 5.5%、差は5.7%）。Shoals Technologies Group, Inc.の前年同期比売上増加率が高い（38.6% vs 29.6%）。ANI PHARMACEUTICALS INCの直近四半期フリーキャッシュフローが多い（$29.1M vs $-11.3M）。過去8四半期でANI PHARMACEUTICALS INCの売上複合成長率が高い（34.1% vs 27.8%）
ANIファーマシューティカルズは米国に本社を置く特殊製薬会社で、後発医薬品とブランド処方薬の研究開発・製造・販売を行っています。主力製品分野は皮膚科、腫瘍、中枢神経系治療、感染症対策で、主に米国内の医療機関、調剤薬局、患者を対象としています。
ショールズテクノロジーグループは、再生可能エネルギー・電動モビリティ分野の電気バランスシステムソリューションプロバイダーです。太陽光発電、蓄電システム、EV充電インフラ向け接続部品を提供し、北米、欧州、アジア太平洋地域の顧客にサービスを展開しています。
ANIP vs SHLS — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $247.1M | $148.3M |
| 純利益 | $27.5M | $8.1M |
| 粗利率 | — | 31.6% |
| 営業利益率 | 14.1% | 11.7% |
| 純利益率 | 11.1% | 5.5% |
| 売上前年比 | 29.6% | 38.6% |
| 純利益前年比 | 367.5% | 3.9% |
| EPS（希薄化後） | $1.14 | $0.05 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $247.1M | $148.3M | ||
| Q3 25 | $227.8M | $135.8M | ||
| Q2 25 | $211.4M | $110.8M | ||
| Q1 25 | $197.1M | $80.4M | ||
| Q4 24 | $190.6M | $107.0M | ||
| Q3 24 | $148.3M | $102.2M | ||
| Q2 24 | $138.0M | $99.2M | ||
| Q1 24 | $137.4M | $90.8M |
| Q4 25 | $27.5M | $8.1M | ||
| Q3 25 | $26.6M | $11.9M | ||
| Q2 25 | $8.5M | $13.9M | ||
| Q1 25 | $15.7M | $-282.0K | ||
| Q4 24 | $-10.3M | $7.8M | ||
| Q3 24 | $-24.2M | $-267.0K | ||
| Q2 24 | $-2.3M | $11.8M | ||
| Q1 24 | $18.2M | $4.8M |
| Q4 25 | — | 31.6% | ||
| Q3 25 | — | 37.0% | ||
| Q2 25 | — | 37.2% | ||
| Q1 25 | — | 35.0% | ||
| Q4 24 | — | 37.6% | ||
| Q3 24 | — | 24.8% | ||
| Q2 24 | — | 40.3% | ||
| Q1 24 | — | 40.2% |
| Q4 25 | 14.1% | 11.7% | ||
| Q3 25 | 15.9% | 13.7% | ||
| Q2 25 | 6.6% | 14.4% | ||
| Q1 25 | 13.3% | 5.4% | ||
| Q4 24 | -2.3% | 15.4% | ||
| Q3 24 | -13.8% | 4.4% | ||
| Q2 24 | 3.7% | 18.7% | ||
| Q1 24 | 14.8% | 12.8% |
| Q4 25 | 11.1% | 5.5% | ||
| Q3 25 | 11.7% | 8.7% | ||
| Q2 25 | 4.0% | 12.5% | ||
| Q1 25 | 8.0% | -0.4% | ||
| Q4 24 | -5.4% | 7.3% | ||
| Q3 24 | -16.3% | -0.3% | ||
| Q2 24 | -1.7% | 11.9% | ||
| Q1 24 | 13.2% | 5.3% |
| Q4 25 | $1.14 | $0.05 | ||
| Q3 25 | $1.13 | $0.07 | ||
| Q2 25 | $0.36 | $0.08 | ||
| Q1 25 | $0.69 | $0.00 | ||
| Q4 24 | $-0.45 | $0.04 | ||
| Q3 24 | $-1.27 | $0.00 | ||
| Q2 24 | $-0.14 | $0.07 | ||
| Q1 24 | $0.82 | $0.03 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $285.6M | $7.3M |
| 総負債低いほど良い | — | — |
| 株主資本純資産 | $540.7M | $600.0M |
| 総資産 | $1.4B | $904.1M |
| 負債/資本比率低いほどレバレッジが低い | — | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $285.6M | $7.3M | ||
| Q3 25 | $262.6M | $8.6M | ||
| Q2 25 | $217.8M | $4.7M | ||
| Q1 25 | $149.8M | $35.6M | ||
| Q4 24 | $144.9M | $23.5M | ||
| Q3 24 | $145.0M | $11.1M | ||
| Q2 24 | $240.1M | $3.2M | ||
| Q1 24 | $228.6M | $15.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $141.8M | ||
| Q4 24 | — | $141.8M | ||
| Q3 24 | — | $141.8M | ||
| Q2 24 | — | $146.8M | ||
| Q1 24 | — | $168.8M |
| Q4 25 | $540.7M | $600.0M | ||
| Q3 25 | $505.8M | $589.6M | ||
| Q2 25 | $436.8M | $575.4M | ||
| Q1 25 | $418.6M | $558.9M | ||
| Q4 24 | $403.7M | $556.8M | ||
| Q3 24 | $405.9M | $545.2M | ||
| Q2 24 | $455.8M | $544.6M | ||
| Q1 24 | $452.0M | $554.0M |
| Q4 25 | $1.4B | $904.1M | ||
| Q3 25 | $1.4B | $851.8M | ||
| Q2 25 | $1.3B | $795.0M | ||
| Q1 25 | $1.3B | $788.4M | ||
| Q4 24 | $1.3B | $793.1M | ||
| Q3 24 | $1.3B | $801.3M | ||
| Q2 24 | $920.8M | $788.4M | ||
| Q1 24 | $914.5M | $825.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.25× | ||
| Q4 24 | — | 0.25× | ||
| Q3 24 | — | 0.26× | ||
| Q2 24 | — | 0.27× | ||
| Q1 24 | — | 0.30× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $30.4M | $-4.1M |
| フリーキャッシュフロー営業CF - 設備投資 | $29.1M | $-11.3M |
| FCFマージンFCF / 売上 | 11.8% | -7.6% |
| 設備投資強度設備投資 / 売上 | 0.5% | 4.8% |
| キャッシュ転換率営業CF / 純利益 | 1.10× | -0.50× |
| 直近12ヶ月FCF直近4四半期 | $171.4M | $-16.0M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $30.4M | $-4.1M | ||
| Q3 25 | $44.1M | $19.4M | ||
| Q2 25 | $75.8M | $-13.8M | ||
| Q1 25 | $35.0M | $15.6M | ||
| Q4 24 | $15.9M | $14.0M | ||
| Q3 24 | $12.5M | $15.7M | ||
| Q2 24 | $17.4M | $37.8M | ||
| Q1 24 | $18.3M | $12.9M |
| Q4 25 | $29.1M | $-11.3M | ||
| Q3 25 | $38.0M | $9.0M | ||
| Q2 25 | $71.8M | $-26.0M | ||
| Q1 25 | $32.5M | $12.3M | ||
| Q4 24 | $13.5M | $12.5M | ||
| Q3 24 | $7.7M | $13.3M | ||
| Q2 24 | $13.0M | $35.8M | ||
| Q1 24 | $13.7M | $10.4M |
| Q4 25 | 11.8% | -7.6% | ||
| Q3 25 | 16.7% | 6.6% | ||
| Q2 25 | 34.0% | -23.5% | ||
| Q1 25 | 16.5% | 15.4% | ||
| Q4 24 | 7.1% | 11.6% | ||
| Q3 24 | 5.2% | 13.0% | ||
| Q2 24 | 9.4% | 36.1% | ||
| Q1 24 | 10.0% | 11.4% |
| Q4 25 | 0.5% | 4.8% | ||
| Q3 25 | 2.7% | 7.7% | ||
| Q2 25 | 1.9% | 11.0% | ||
| Q1 25 | 1.3% | 4.0% | ||
| Q4 24 | 1.3% | 1.4% | ||
| Q3 24 | 3.2% | 2.3% | ||
| Q2 24 | 3.2% | 2.0% | ||
| Q1 24 | 3.3% | 2.7% |
| Q4 25 | 1.10× | -0.50× | ||
| Q3 25 | 1.66× | 1.63× | ||
| Q2 25 | 8.87× | -1.00× | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | — | 1.79× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 3.21× | ||
| Q1 24 | 1.00× | 2.69× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
SHLS
| System Solutions | $122.0M | 82% |
| Components | $26.3M | 18% |
